YAG Stock Chart & Stats
€2.24
€0.10(5.05%)
At close: 4:00 PM EDT
€2.24
€0.10(5.05%)
Day’s Range― - ―
52-Week Range€1.52 - €16.23
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€20.74M
Enterprise Value-€9.01
Total Cash (Recent Filing)€26.09M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Nov 16, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.34
Shares Outstanding9,979,298
10 Day Avg. Volume47
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.77Price Target Upside336.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.39
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free structure avoids refinancing and interest-rate burdens while ATOS funds clinical development. That preserves flexibility to direct capital toward trials and reduces fixed financial obligations, although it does not by itself solve the company’s cash-consumption needs.
Clinical Pipeline ProgressClinical progress provides tangible advancement for the lead (Z)-Endoxifen program, moving it beyond early development and supporting potential future indications. Completion of EVANGELINE enrollment and I-SPY2 activity can create additional data milestones that sharpen the pipeline’s strategic value.
Rare-disease OptionalityRare pediatric disease designations create a differentiated regulatory and commercial opportunity around (Z)-endoxifen. The CVR plan also gives shareholders contractual participation in potential voucher proceeds, adding structured upside optionality as the company advances its rare-disease programs.
Bears Say
No Commercial RevenueThe absence of commercial revenue means ATOS has not yet demonstrated product-market monetization or recurring operating income. Funding remains dependent on advancing clinical assets toward approval, leaving financial performance highly sensitive to trial outcomes, regulatory progress, and future financing access.
Accelerating Cash BurnIncreasing operating cash burn shows that the business is not self-funding and that clinical development is consuming cash at a rising rate. Continued negative operating and free cash flow increases pressure to secure additional capital, potentially constraining program choices and execution flexibility.
Shrinking Equity BaseThe substantial decline in equity and assets reflects cumulative losses and ongoing cash usage, weakening the financial cushion available for development. If this trajectory continues, ATOS may need further capital to sustain operations, creating a risk of value dilution and less flexibility in allocating resources.
Atossa Therapeutics News
YAG FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was €1.52 and its highest was €16.23 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is €20.74M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 43 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Aug 07, 2026. The company reported -€0.844 earnings per share for the quarter, beating the consensus estimate of -€0.91 by €0.067.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -0.76.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 9,979,298 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -€0.844 in its last earnings report, beating expectations of -€0.91. Following the earnings report the stock price went up 0.99%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in DE:YAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
YAG Stock 12 Month Forecast
Average Price Target
€9.77
▲(336.15% Upside)